Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 2,431 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $4.94, for a total value of $12,009.14. Following the completion of the sale, the director now directly owns 66,432 shares in the company, valued at $328,174.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Thursday, August 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.25, for a total value of $15,193.75.

Fennec Pharmaceuticals Price Performance

Shares of FENC opened at $4.52 on Friday. The firm has a market capitalization of $123.52 million, a price-to-earnings ratio of 150.67 and a beta of 0.26. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.75 and a current ratio of 8.02. Fennec Pharmaceuticals Inc has a one year low of $4.50 and a one year high of $11.92. The stock’s fifty day moving average is $5.52 and its 200-day moving average is $7.24.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $7.26 million for the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 53.38%. During the same period last year, the business posted ($0.21) earnings per share. Equities analysts anticipate that Fennec Pharmaceuticals Inc will post -0.07 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of FENC. Essex Investment Management Co. LLC acquired a new position in shares of Fennec Pharmaceuticals during the first quarter valued at $1,604,000. WINTON GROUP Ltd bought a new position in Fennec Pharmaceuticals during the second quarter valued at about $409,000. Russell Investments Group Ltd. boosted its stake in Fennec Pharmaceuticals by 71,275.0% during the first quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock valued at $381,000 after buying an additional 34,212 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Fennec Pharmaceuticals by 42.8% during the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock valued at $420,000 after buying an additional 20,602 shares in the last quarter. Finally, Gendell Jeffrey L boosted its stake in Fennec Pharmaceuticals by 7.1% during the first quarter. Gendell Jeffrey L now owns 302,478 shares of the company’s stock valued at $3,364,000 after buying an additional 20,000 shares in the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on FENC shares. HC Wainwright dropped their target price on Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, August 22nd. Craig Hallum dropped their target price on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, Wedbush reissued an “outperform” rating and set a $14.00 price target (down from $16.00) on shares of Fennec Pharmaceuticals in a report on Tuesday, August 13th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.